Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Improving Access to Cosmetic Dermatology: A Longitudinal Analysis of the Public Interest of Argireline
ABSTRACT
Background:
Argireline, a topical, short-acting neurotoxin, has recently gained popularity for its anti-wrinkle effects and has emerged as a more accessible alternative to Botulinum neurotoxin (BoNT).
Objective:
This study evaluates public interest of Argireline in the United States from 2013 to 2023, as described by search volume on Google, the most-used search engine.
Methods:
Longitudinal relative monthly search volume from January 1, 2013, to January 1, 2023, was analyzed for Argireline-related terms. Internet search trends for “Botox” during this period were compared to “Argireline” and state-specific interest was identified.
Results:
Terms “Argireline” and “Botox in a bottle” both had significant increases in search volume in 2022. Although its search volume is drastically increasing, “Argireline” was significantly less searched than “Botox,” which had a stable, up-trending search volume over the past decade.
Conclusions:
The increasing interest in Argireline may be due to its cost efficacy and use as a BoNT alternative. Argireline’s affordability, over-the-counter availability, and ease of self-application suggest its potential to enhance accessibility to cosmetic dermatologic care.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.